Verona cues up filings for COPD drug after it aces phase 3 test
UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory […]
UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory […]
Acute Respiratory Distress Syndrome (ARDS) is a growing and concerning unmet medical need with no effective therapeutic, and a serious medical burden in a world […]
Pfizer’s Australian unit has tabled an offer to buy ResApp Health and its smartphone apps for the management and diagnosis of respiratory diseases in a […]
Data from a massive real-world study of asthma patients has suggested that overuse of inhalers is widespread and leading to an elevated risk of severe […]
Novartis may be planning to sell off its generics business Sandoz, but that hasn’t stopped it investing in the unit ahead of a decision on […]
UK biotech Synairgen saw the value of its shares crater after its inhaled interferon beta therapy SNG001 was found to provide no benefit to people […]
People with long-lasting symptoms of breathlessness after COVID-19 infection may have damage to their lungs that does not show up using routine diagnostic scans, according […]
US company Respira Labs has developed a device worn on the chest that uses tiny speakers and microphones to project sound into the lungs and […]
18 months after saying “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed […]
Amgen and AstraZeneca haven’t won approval or announced a price for their severe asthma therapy tezepelumab should it reach the market, but ICER in the […]
Tobacco giant Philip Morris International (PMI) has won the shareholder vote it needed for its controversial £1.1 billion takeover of respiratory drugmaker Vectura, despite mobilised […]
Amgen and partner AstraZeneca have said their recently filed severe asthma drug tezepelumab has shown impressive results in patients who also have nasal polyps, a […]
Private equity group Carlyle has said it won’t raise its offer for respiratory drug specialist Vectura to match a 165p per share offer from tobacco […]
A flurry of new offers by Philip Morris International (PMI) and private equity firm Carlyle has hiked the value of respiratory medicines company Vectura to […]
Tobacco giant Philip Morris International (PMI) has doubled down on its move into the pharmaceutical sector, following up its recent acquisition of Fertin Pharma with […]
Sonde Health has joined forces with chipmaker Qualcomm to develop a technology platform that could diagnose human health conditions from a short sample of speech. […]
Vectura has agreed to a £1.55 per share takeover by US private investment company Carlyle, which values the UK drug delivery specialist at £958 million […]
Drugmaker Chiesi has set up an online community to provide support to respiratory nurses, who have faced unprecedented challenges in the last year as they […]
The FDA has extended a collaboration with the UK firm CN Bio to investigate a “lung-on-a-chip” model to investigate inhaled drugs. In a statement the […]
Health Data Research UK’s respiratory hub BREATHE is set to use artificial intelligence (AI) to unlock real-world insights from electronic health records (EHRs) as part […]
A smartphone app that uses artificial intelligence to assess the sound of coughing has been launched in the UK, and according to its developer could […]
A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing blockbuster. The US District Court for the […]
AstraZeneca says full data from the NAVIGATOR trial of tezepelumab in severe asthma keep it on course to file for approval in the first half […]
UK-based Verona Pharma has scored a new win with its chronic obstructive pulmonary disease (COPD) drug ensifenitrine, after a formulation delivered with an inhaler met […]
UK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19 patients, after encouraging topline results from a phase 2 […]
Shots: The P-II trial will assess BI 764198 (qd for ~4wks.) in patients hospitalized for COVID-19 with expected enrollment initiation in Oct’2020. The 1EPs will […]
Copyright © 2024 | WordPress Theme by MH Themes